(Q43139881)

14 November 2017

title

An in vitro assay to measure targeted drug delivery to bone mineral (English)

1 reference

14 November 2017

1 reference

Wolfgang Jahnke

1

1 reference

14 November 2017

Chrystèle Henry

series ordinal

2

1 reference

14 November 2017

publication date

1 May 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

5

1 reference

14 November 2017

issue

5

1 reference

14 November 2017

page(s)

770-776

1 reference

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bisphosphonate actions: physical chemistry revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Thermodynamics of bisphosphonates binding to human bone: a two-site model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Differences between bisphosphonates in binding affinities for hydroxyapatite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Library design for fragment based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bisphosphonates as a foundation of drug delivery to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bone as an effect compartment : models for uptake and release of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

An EP2 receptor-selective prostaglandin E 2 agonist induces bone healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Selective drug delivery system to bone: small peptide (Asp)6 conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

Simulating hydroxyapatite binding of bone-seeking bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Ranking of high-affinity ligands by NMR spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Structural requirements for bisphosphonate actions in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000016

7 January 2021

Identifiers

DOI

10.1002/CMDC.201000016

1 reference

14 November 2017

1 reference